SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway

British Journal of Pharmacology

Volumn 159, Issue 3, 2010, Pages 689-697

  Xie, Gui'E ^a,b,c   Zhu, Xun ^a,b,c   Li, Qing ^a,b   Gu, Minghui ^a,b   He, Zhenjian ^a,b,c   Wu, Jueheng ^a,b,c   Li, Jun ^a,b,c   Lin, Yongcheng ^a,b   Li, Mengfeng ^a,b,c   She, Zhigang ^a,b   Yuan, Jie ^a,b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b Bureau of Education   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Breast cancer; SZ 685C

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; FORKHEAD TRANSCRIPTION FACTOR; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN KINASE B; SZ 685C; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIVER CELL CARCINOMA; MANGROVE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; XENOGRAFT;

ADENOSINE DIPHOSPHATE RIBOSE; ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; FEMALE; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TETRAZOLIUM SALTS; THIAZOLES;

EID: 76449101999     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00577.x     Document Type: Article

References (33)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M (2003). Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 14 : 1607 1615.
3. Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM (2008). Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71 : 492 496.
4. Bliss C (1935). The calculation of the dose-mortality curve. Ann Appl Biol 22 : 134 167.
5. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 : 857 868.
6. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003). Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97 : 545 553.
7. Chien AJ, Moasser MM (2008). Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35 (Suppl. 2 1 14.
8. D'Incalci M, Simone M, Tavecchio M, Damia G, Garbi A, Erba E (2004). New drugs from the sea. J Chemother 16 (Suppl. 86 89.
9. Fesik SW (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 : 876 885.
10. Fulda S, Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 : 4798 4811.
11. Ghobrial IM, Witzig TE, Adjei AA (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55 : 178 194.
12. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008). Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26 : 3777 3784.
13. Gilley J, Coffer PJ, Ham J (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162 : 613 622.
14. Hengartner MO (2000). The biochemistry of apoptosis. Nature 407 : 770 776.
15. Hofland KF, Thougaard AV, Sehested M, Jensen PB (2005). Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 11 : 3915 3924.
16. Lee S, Choi EJ, Jin C, Kim DH (2005). Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97 : 26 34.
17. LoPiccolo J, Granville CA, Gills JJ, Dennis PA (2007). Targeting Akt in cancer therapy. Anticancer Drugs 8 : 861 874.
18. Lu S, Ren C, Liu Y, Epner DE (2006). PI3K-Akt signaling is involved in the regulation of p21 (WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol 28 : 245 251.
19. Moon IJ, Choi K, Choi YK, Kim JE, Lee Y, Schreiber AD et al. (2000). Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. J Biol Chem 275 : 4647 4653.
20. O'Hanlon LH (2006). Scientists are searching the seas for cancer drugs. J Natl Cancer Inst 98 : 662 663.
21. Perez EA (2009). Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114 : 195 201.
22. Romashkova JA, Makarov SS (1999). NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401 : 86 90.
23. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30 : 181 191.
24. Schwartsmann G, Da Rocha AB, Mattei J, Lopes R (2003). Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 12 : 1367 1383.
25. Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS et al. (2000). Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60 : 1435 1444.
26. She ZG, Chen SP, Lin YC, Yuan J, Pang JY, Li MF et al. (2008). SZ-685C preparation method and antitumor application. Application No: 00810028628.3, Aplication Date: 2008.6.6.
27. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH (2005). Marine natural products as anticancer drugs. Mol Cancer Ther 4 : 333 342.
28. Sunters A, Fernzyxonefiveninexyzndez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA et al. (2003). FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278 : 49795 49805.
29. Vegran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S (2006). Overexpression of caspase-3 splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 12 : 5794 5800.
30. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 : 489 501.
31. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D (2008). Forkhead box-O transcription factor: critical conductors of cancerzyxonethreetwoxyz fate. Endocr Relat Cancer 15 : 917 929.
32. West KA, Castillo SS, Dennis PA (2002). Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5 : 234 248.
33. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K et al. (2004). Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10 : 2846 2850.